ArticleCureus2026
Comparative Analysis of Albumin-Bilirubin (ALBI) Score and Child-Pugh Score for Prognostic Stratification in Hepatocellular Carcinoma Patients: A Single-Center Experience From North India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Accurate assessment of hepatic reserve is essential in hepatocellular carcinoma (HCC). While the Child-Pugh (CP) score remains widely used, subjectivity in its parameters limits reproducibility. The Albumin-Bilirubin (ALBI) score offers an objective alternative, but contemporary Indian data comparing the two remain limited. Aim To compare the prognostic performance of the Child-Pugh (CP) score, the ALBI score, and the modified ALBI (mALBI) grade in predicting survival outcomes among patients with hepatocellular carcinoma treated at a North Indian tertiary cancer center using an extended follow-up dataset. Methods This retrospective cohort included consecutive patients diagnosed with HCC between January 2020 and December 2024. Eligibility required radiologic or histologic HCC and baseline CP class A or B. ALBI and CP scores were calculated at diagnosis. Survival analysis was censored on June 30, 2025, providing mature overall survival (OS) and progression-free survival (PFS) data (median follow-up 24.0 months). Kaplan-Meier methods, Cox regression, Harrell's C-index, and time-dependent receiver operating characteristic (ROC) analyses were performed. Results A total of 210 patients were included. ALBI grade distribution was ALBI-1 in 67 patients (31.9%), ALBI-2 in 125 patients (59.5%), and ALBI-3 in 18 patients (8.6%). Child-Pugh classification showed CP-A in 155 patients (74.0%) and CP-B in 55 patients (26.0%). Median OS for the cohort was 14.2 months (95% CI: 11.8-16.9), and median PFS was 9.5 months (95% CI: 7.8-11.4). ALBI demonstrated superior prognostic discrimination compared with Child-Pugh classification (C-index 0.68 vs. 0.61, p=0.024), while modified ALBI showed the highest discriminatory performance (C-index 0.71). ALBI also identified significant prognostic heterogeneity within CP-A patients that was not captured by Child-Pugh classification. Conclusion In this retrospective single-center cohort, the ALBI score demonstrated better prognostic discrimination than the Child-Pugh score, particularly among patients with Child-Pugh class A liver function. These findings support consideration of ALBI as an objective tool for risk stratification in HCC; however, prospective multicenter studies are needed to validate its broader clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.